Maze Therapeutics said on Thursday that it raised $140 million in an initial public offering, setting the stage for a debut that will make the kidney disease drug developer the first U.S. biotech ...
(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...
Bond manager’s $7 billion stake in Venture Global latest sign that traditional asset managers are making inroads investing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback